Vertex Pharma (VRTX) Tops Q2 EPS by 3c, raises guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $558.65 +0.34%
Revenue Growth %: +10.7%
Financial Fact:
Research and development expenses: 272.37M
Today's EPS Names:
VIVO, PMCB, PLCE, More
Revenue Growth %: +10.7%
Financial Fact:
Research and development expenses: 272.37M
Today's EPS Names:
VIVO, PMCB, PLCE, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $3.89, $0.03 better than the analyst estimate of $3.86. Revenue for the quarter came in at $2.49 billion versus the consensus estimate of $2.42 billion.
Guidance:
Company raises full year 2023 product revenue guidance to $9.7 to $9.8 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Adjust Monthly US Director's Cut List
- Bernstein SocGen on DoorDash Inc. (DASH): 'What now for the stock?'
- Duluth Holdings Inc. (DLTH) Tops Q2 EPS by 49c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
